Inozyme Pharma

105 articles about Inozyme Pharma

• Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

  4/8/2024

  Inozyme Pharma, Inc. announced positive topline safety, pharmacokinetic, pharmacodynamic and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency.

• Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 05, 2024

  4/5/2024

  Inozyme Pharma, Inc. announced that it granted stock options to three new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, as inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635.

• Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference

  4/2/2024

  Inozyme Pharma, Inc today announced that Doug Treco, Ph.D., the company’s chief executive officer and chairman of the board, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024.

• Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

  3/26/2024

  Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host a conference call and webcast on Monday, April 8, 2024 at 8:00 a.m. Eastern Time.

• Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

  3/12/2024

  Inozyme Pharma, Inc. today reported financial results for the full year ended December 31, 2023, and provided recent business highlights.

• Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference- Douglas A. Treco, Ph.D., CEO and Chairman, to participate in panel discussion -

  2/26/2024

  Inozyme Pharma, Inc. today announced Douglas A. Treco, Ph.D., the Company’s chief executive officer and chairman of the board, will participate in an Orphan Bone & Neuromuscular Diseases panel presentation at the TD Cowen 44th Annual Health Care Conference.

• Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 6, 2024

  2/6/2024

  Inozyme Pharma, Inc. today announced that it granted stock options to four new employees to purchase shares of the Company’s common stock.

• Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 05, 2023

  12/5/2023

  Inozyme Pharma, Inc. announced that it granted stock options to a new employee to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, as inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635.

• Inozyme Pharma to Participate in Upcoming Investor Conferences - November 9, 2023

  11/9/2023

  Inozyme Pharma, Inc. today announced that Douglas A. Treco, Ph.D., the Company’s chief executive officer and chairman of the board, will participate at the following investor conferences.

• Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

  11/7/2023

  Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the third quarter ended September 30, 2023 and provided business highlights.

• Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 03, 2023

  11/3/2023

  Inozyme Pharma, Inc. announced that it granted stock options to new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635.

• Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023

  10/26/2023

  Inozyme Pharma, Inc. today announced an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2023, which is being held November 2-5, 2023 in Philadelphia, PA.

• Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting

  10/6/2023

  Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will present three posters at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held October 13-16, 2023 in Vancouver, BC, Canada.

• Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

  9/26/2023

  Inozyme Pharma, Inc. today announced positive interim safety, pharmacokinetic (PK), pharmacodynamic (PD) and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE, pseudoxanthoma elasticum).

• Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023

  9/20/2023

  Inozyme Pharma, Inc. today announced that it will host an Investor and Analyst Event on Tuesday, September 26, 2023 at 8:00 a.m. Eastern Time.

• Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  9/6/2023

  Inozyme Pharma, Inc. today announced that it granted stock options to a new employee to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan.

• Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

  9/5/2023

  Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company’s chief executive officer and chairman of the board, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, from 12:00-12:30pm ET.

• Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights

  8/8/2023

  Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the second quarter ended June 30, 2023, and provided business highlights.

• Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 03, 2023

  8/3/2023

  Inozyme Pharma, Inc. announced that the Company granted stock options to new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635.

• Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock - August 01, 2023

  8/1/2023

  Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, announced the closing of its underwritten public offering of 14,375,000 shares of its common stock at a price of $4.80 per share.